Recombinant fusion proteins for preventing or treating adhesions of tissues or organs

A method for preparing a pharmaceutical composition, comprising combining a recombinant fusion protein comprising ancrod, or a recombinant variant of ancrod having fibrinogenolytic activity, wherein the ancrod or variant ancrod is connected by a linker at the C-terminal amino acid to the N-terminus of an amino acid sequence of at least one high-molecular weight inert stabilization domain with a molecular weight of >50 kDa that provides non-specific bonding to a mesothelium surface lining a peritoneal cavity of a patient and reduces transport of the fusion protein through a peritoneal membrane, the inert stabilization domain comprising a dimer or a multimer of an IgG-Fc antibody fragment, and a pharmaceutically acceptable carrier comprising a biodegradable matrix for continuous intraperitoneal release of the recombinant fusion protein.